Ligand Pharmaceuticals Quarterly Income Statement
NASDAQ: LGNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ligand Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Ligand Pharmaceuticals generated $63.7 million in revenue, up 33.7% from the same quarter a year earlier. Net income was $48.5 million (+900.8% year over year), for a net margin of 76.2% versus a median of 10.2% in the prior 5 quarters. Operating margin was 13.5%.
Diluted earnings per share came in at $2.22, up from $0.24.
Summary generated from market data by MetaCap's automated system. Methodology
Ligand Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 63.69M | 51.72M | 59.67M | 115.46M | 47.63M | 45.33M | 42.81M | 51.81M | 41.53M | 30.98M | 28.10M | 32.87M |
| Revenue growth (YoY) | +33.73% | +14.09% | +39.37% | +122.85% | +14.68% | +46.34% | +52.35% | +57.64% | +57.52% | -29.56% | -44.22% | -44.50% |
| Research & Development | 14.67M | 2.15M | 3.51M | 21.02M | 6.57M | 50.09M | 4.42M | 5.67M | 5.35M | 5.97M | 5.49M | 5.53M |
| Operating Income | 8.59M | 17.37M | 13.84M | 54.93M | 8.44M | -36.22M | -9.64M | 3.14M | -19.10M | 2.99M | -3.36M | 3.08M |
| Interest Expense | 1.75M | 1.75M | 1.78M | 910.00K | 1.15M | 867.00K | 883.00K | 741.00K | 1.27M | 141.00K | 131.00K | 1.00K |
| Other Income (Expense) | 55.71M | -41.63M | 42.94M | 86.21M | 2.78M | -13.96M | -29.56M | -9.48M | -46.29M | 110.46M | 20.45M | -15.22M |
| Pretax Income | 64.30M | -24.26M | 56.78M | 141.14M | 11.22M | -50.18M | -39.20M | -6.34M | -65.39M | 113.45M | 17.10M | -12.14M |
| Income Tax | 15.80M | -10.91M | 12.00M | 23.86M | 6.38M | -7.73M | -8.11M | 833.00K | -13.48M | 27.31M | -1.09M | -1.87M |
| Net Income | 48.51M | -13.35M | 44.78M | 117.27M | 4.85M | -42.45M | -31.09M | -7.17M | -51.91M | 86.14M | 18.19M | -10.27M |
| Net Income growth (YoY) | +900.78% | — | — | — | — | -149.28% | -270.93% | — | -2366.86% | +105.34% | — | -2642.82% |
| EPS (Basic) | 2.42 | -0.67 | 2.41 | 5.99 | 0.25 | -2.21 | -1.81 | -0.39 | -2.88 | 4.86 | 1.02 | -0.59 |
| EPS (Diluted) | 2.22 | -0.67 | 2.42 | 5.68 | 0.24 | -2.21 | -1.70 | -0.39 | -2.88 | 4.75 | 1.07 | -0.59 |
| Shares Outstanding (Basic) | 20.06M | 19.88M | — | 19.58M | 19.33M | 19.19M | — | 18.42M | 18.03M | 17.73M | — | 17.38M |
| Shares Outstanding (Diluted) | 21.84M | 19.88M | — | 20.63M | 19.93M | 19.19M | — | 18.42M | 18.03M | 18.12M | — | 17.38M |
| EBITDA | 16.81M | 25.58M | 22.06M | 63.20M | 16.97M | -27.45M | -1.01M | 12.14M | -10.25M | 11.75M | 5.56M | 11.69M |
| Operating Margin | 13.49% | 33.58% | 23.20% | 47.58% | 17.73% | -79.89% | -22.51% | 6.07% | -45.99% | 9.65% | -11.95% | 9.36% |
| Net Margin | 76.16% | -25.80% | 75.06% | 101.57% | 10.18% | -93.64% | -72.62% | -13.84% | -124.99% | 278.07% | 64.72% | -31.26% |
This table shows 12 quarterly periods of Ligand Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow LGND's reporting calendar. What is a income statement?